✦ LIBER ✦

Who is an “older” patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials

✍ Scribed by Mohamed, Imran; Hills, Robert K.; Burnett, Alan K.

Book ID: 121691812
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 113 KB
Volume: 165
Category: Article
ISSN: 0007-1048
DOI: 10.1111/bjh.12705

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Karyotype is an independent prognostic p

Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML

✍ Schoch, C; Kern, W; Schnittger, S; Hiddemann, W; Haferlach, T 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 166 KB

Temsirolimus, an mTOR inhibitor, in comb

Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)

✍ Sergio Amadori; Roberto Stasi; Alberto M. Martelli; Adriano Venditti; Giovanna M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 196 KB

The impact of dose escalation and resist

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

✍ Alan K. Burnett; Donald Milligan; Anthony Goldstone; Archibald Prentice; Mary-Fr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 420 KB

Randomized trial of two schedules of low

Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)

✍ Sergio Amadori; Stefan Suciu; Dominik Selleslag; Roberto Stasi; Giuliana Alimena 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

PRDX4, a member of the peroxiredoxin fam

PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22)

✍ Yanming Zhang; Neelmini Emmanuel; Ginny Kamboj; Jianjun Chen; Muhammad Shurafa; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB 👁 1 views

## Abstract The __AML1__ gene (also known as __RUNX1__) at 21q22 codes for core binding factor (CBF) α, which forms a heterodimer with CBF β that acts as a transcriptional activating factor. CBF is a critical regulator in the generation and differentiation of definitive hematopoietic stem cells and